E-MAIL UPDATES

Click here to join

Investors & Media

What's new.

Press releases

Press releases.

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

November 29th 2022
press releases

Immutep Receives Australian R&D Tax Incentive

November 14th 2022
press releases

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

November 11th 2022
press releases
more

Investor updates

Investor updates.

Investor Update - November 2022

November 17th 2022
investor updates

Investor Update ASCO 2022 Special Edition June 2022

June 17th 2022
investor updates

Investor Update - February 2022

February 18th 2022
investor updates
more

Analyst reports

Analyst reports.

CLSA Equity Research - Immutep (IMM) announces a new collaboration with Merck KGaA and Pfizer for a Ph 1 clinical trials for metastatic urothelial cancer (INSIGHT-005) (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

November 29th 2022
analyst reports

Petra Capital - Immutep Limited (IMM) - New clinical trial collaboration with Merck KGaA/Pfizer for Phase 1 with efti in urothelial cancer, a positive with more to come (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

November 29th 2022
analyst reports

Wilsons Equity Research - Immutep Limited (IMM) | Keytruda isn’t the only kid in the Efti sandbox (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

November 29th 2022
analyst reports
more